$3.13
Erasca is a biotechnology business based in the US. Erasca shares (ERAS) are listed on the NASDAQ and all prices are listed in US Dollars. Erasca employs 126 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy Erasca stock
How to buy Erasca stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ERAS. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Erasca stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Erasca stock price (NASDAQ: ERAS)
Use our graph to track the performance of ERAS stocks over time.Erasca shares at a glance
Latest market close | $3.14 |
---|---|
52-week range | $1.51 - $3.33 |
50-day moving average | $2.39 |
200-day moving average | $2.13 |
Wall St. target price | $4.57 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.84 |
Is it a good time to buy Erasca stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Erasca price performance over time
Historical closes compared with the close of $3.14 from 2024-07-22
1 week (2024-07-17) | -1.57% |
---|---|
1 month (2024-06-24) | 45.37% |
3 months (2024-04-24) | 67.02% |
6 months (2024-01-24) | 85.80% |
1 year (2023-07-24) | 21.24% |
---|---|
2 years (2022-07-22) | -57.97% |
3 years (2021-07-23) | 19.12 |
5 years (2019-07-20) | N/A |
Erasca financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -21.39% |
Return on equity TTM | -37.6% |
Profit margin | 0% |
Book value | $1.91 |
Market Capitalization | $804.8 million |
TTM: trailing 12 months
Erasca share dividends
We're not expecting Erasca to pay a dividend over the next 12 months.
Erasca share price volatility
Over the last 12 months, Erasca's shares have ranged in value from as little as $1.51 up to $3.3251. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Erasca's is 1.162. This would suggest that Erasca's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put Erasca's beta into context you can compare it against those of similar companies.
- Adaptive Biotechnologies (ADPT.US): 1.347
- Inovio Pharmaceuticals (INO.US): 0.895
- Neximmune (NEXI.US): 1.937
Erasca overview
Erasca, Inc. , a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc.
Frequently asked questions
nullWhat percentage of Erasca is owned by insiders or institutions?
Currently 14.716% of Erasca shares are held by insiders and 55.738% by institutions. How many people work for Erasca?
Latest data suggests 126 work at Erasca. When does the fiscal year end for Erasca?
Erasca's fiscal year ends in December. Where is Erasca based?
Erasca's address is: 3115 Merryfield Row, San Diego, CA, United States, 92121 What is Erasca's ISIN number?
Erasca's international securities identification number is: US29479A1088
More guides on Finder
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
Put options explained
Learn the basics of put options: what they are, how they work and a few examples.
-
Frec review 2024: Low-cost direct indexing and individual stock trading
A deep dive into the highlights and limitations of Frec.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
11 apps like Webull you need to consider
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question